
Chronic Myelocytic Leukemia (CML) - Pipeline Insight, 2024
Description
Chronic Myelocytic Leukemia (CML) - Pipeline Insight, 2024
DelveInsight’s, “Chronic Myelomonocytic Leukaemia (CML) - Pipeline Insight, 2024,” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Chronic Myelomonocytic Leukaemia (CML) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Chronic Myelomonocytic Leukaemia (CML): Overview
Chronic Myelomonocytic Leukaemia (CML) (CMML) is a form of leukaemia that is characterised by high numbers of white blood cells, called ‘monocytes’, in the blood and bone marrow. CMML is an uncommon blood cancer with features of two other types of blood cancer. Even though it has leukaemia as part of its name, the World Health Organisation (WHO) classifies CMML as a ‘mixed myelodysplastic (MDS) myeloproliferative neoplasm (MPN)’. MPN is a group of disorders of the bone marrow stem cells that produce excess numbers of one or more types of blood cells (red cells, white cells, or platelets). MDS is a group of diseases that affects, to a greater or lesser extent, the production of normal blood cells in the bone marrow.
""Chronic Myelomonocytic Leukaemia (CML) - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chronic Myelomonocytic Leukaemia (CML) pipeline landscape is provided which includes the disease overview and Chronic Myelomonocytic Leukaemia (CML) treatment guidelines. The assessment part of the report embraces, in depth Chronic Myelomonocytic Leukaemia (CML) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chronic Myelomonocytic Leukaemia (CML) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Chronic Myelomonocytic Leukaemia (CML) R&D. The therapies under development are focused on novel approaches to treat/improve Chronic Myelomonocytic Leukaemia (CML).
This segment of the Chronic Myelomonocytic Leukaemia (CML) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Chronic Myelomonocytic Leukaemia (CML) Emerging Drugs
- Sabatolimab: Novarits Oncology
- Enasidenib: Servier
Further product details are provided in the report……..
Chronic Myelomonocytic Leukaemia (CML): Therapeutic Assessment
This segment of the report provides insights about the different Chronic Myelomonocytic Leukaemia (CML) drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Chronic Myelomonocytic Leukaemia (CML)
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- intravitreal
- Subretinal
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Chronic Myelomonocytic Leukaemia (CML): Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Chronic Myelomonocytic Leukaemia (CML) therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chronic Myelomonocytic Leukaemia (CML) drugs.
Chronic Myelomonocytic Leukaemia (CML) Report Insights
- Chronic Myelomonocytic Leukaemia (CML) Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Chronic Myelomonocytic Leukaemia (CML) drugs?
- How many Chronic Myelomonocytic Leukaemia (CML) drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chronic Myelomonocytic Leukaemia (CML)?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Chronic Myelomonocytic Leukaemia (CML) therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Chronic Myelomonocytic Leukaemia (CML) and their status?
- What are the key designations that have been granted to the emerging drugs?
- Novarits Oncology
- Servier
- Eltrombopag
- Immune-Onc Therapeutics
- H3 Biomedicine
- Chroma Therapeutics
- Nerviano Medical Sciences
- Astex Pharmaceuticals
- Takeda Oncology
- Argenx
- Kura Oncology
- Incyte Corporation
- Genentech, Inc.
- Sensei Biotherapeutics
- Pfizer
- BioLite, Inc.
- Newave Pharmaceutical Inc
- Ellipses Pharma
- Eli Lilly and Company
- Aprea Therapeutics
- Treadwell Therapeutics
- Prelude Therapeutics
- Onconova Therapeutics
- Immune Pharmaceuticals
- Teva Pharmaceutical Industries
- Sabatolimab
- Enasidenib
- IO 202
- H3B 8800
- Tefinostat
- NMS 03592088
- Guadecitabine
- Pevonedistat
- Cusatuzumab
- Tipifarnib
- Ruxolitinib
- Venetoclax
- SNS-301
- Cobimetinib
- Glasdegib
- BLEX 404
- LP-108
- Canakinumab
- EP0042
- LY3410738
- APR-246
- CFI-400945
- PRT543
- Rigosertib
- Histamine dihydrochloride injection
- Arsenic trioxide
Table of Contents
60 Pages
- Introduction
- Executive Summary
- Chronic Myelomonocytic Leukaemia (CML): Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Chronic Myelomonocytic Leukaemia (CML) – DelveInsight’s Analytical Perspective
- In-depth Commercial Assessment
- Chronic Myelomonocytic Leukaemia (CML) companies’ collaborations, Licensing, Acquisition -Deal Value Trends
- Chronic Myelomonocytic Leukaemia (CML) Collaboration Deals
- Company-Company Collaborations (Licensing / Partnering) Analysis
- Company-University Collaborations (Licensing / Partnering) Analysis
- Late Stage Products (Phase III)
- Comparative Analysis
- Sabatolimab: Novartis
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- Tefinostat: Chroma Therapeutics
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- Enasidenib: Servier
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Chronic Myelomonocytic Leukaemia (CML) Key Companies
- Chronic Myelomonocytic Leukaemia (CML) Key Products
- Chronic Myelomonocytic Leukaemia (CML)- Unmet Needs
- Chronic Myelomonocytic Leukaemia (CML)- Market Drivers and Barriers
- Chronic Myelomonocytic Leukaemia (CML)- Future Perspectives and Conclusion
- Chronic Myelomonocytic Leukaemia (CML) Analyst Views
- Chronic Myelomonocytic Leukaemia (CML) Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.